RT Journal Article
SR Electronic
T1 Inhibitor screening of Spike variants reveals the heterogeneity of neutralizing antibodies to COVID-19 infection and vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.15.21257254
DO 10.1101/2021.05.15.21257254
A1 Zhang, Xiaomei
A1 Zheng, Mei
A1 Liang, Te
A1 Zhou, Haijian
A1 Wang, Hongye
A1 Zhang, Jiahui
A1 Ren, Jing
A1 Peng, Huoying
A1 Li, Siping
A1 Bian, Haodong
A1 Wei, Chundi
A1 Yin, Shangqi
A1 He, Chaonan
A1 Han, Ying
A1 Li, Minghui
A1 Hou, Xuexin
A1 Zhang, Jie
A1 Xie, Liangzhi
A1 Lv, Jing
A1 Kan, Biao
A1 Wang, Yajie
A1 Yu, Xiaobo
YR 2021
UL http://medrxiv.org/content/early/2021/05/18/2021.05.15.21257254.abstract
AB Mutations of the coronavirus responsible for coronavirus disease 2019 (COVID-19) could impede drug development and reduce the efficacy of COVID-19 vaccines. Here, we developed a multiplexed Spike-ACE2 Inhibitor Screening (mSAIS) assay that can measure the neutralizing effect of antibodies across numerous variants of the coronavirus’s Spike (S) protein simultaneously. By screening purified antibodies and serum from convalescent COVID-19 patients and vaccinees against 72 S variants with the mSAIS assay, we identified new S mutations that are sensitive and resistant to neutralization. Serum from both infected and vaccinated groups with a high titer of neutralizing antibodies (NAbs) displayed a broader capacity to neutralize S variants than serum with low titer NAbs. These data were validated using serum from a large vaccinated cohort (n=104) with a tiled S peptide microarray. In addition, similar results were obtained using a SARS-CoV-2 pseudovirus neutralization assay specific for wild-type S and four prevalent S variants (D614G, B.1.1.7, B.1.351, P.1), thus demonstrating that high antibody diversity is associated with high NAb titers. Our results demonstrate the utility of the mSAIS platform in screening NAbs. Moreover, we show that heterogeneous antibody populations provide a more protective effect against S variants, which may help direct COVID-19 vaccine and drug development.HighlightsDeveloped a high throughput assay to screen the neutralizing effect of antibodies across multiple SARS-CoV-2 Spike variants simultaneously.Characterized the heterogeneity of neutralizing antibodies produced in response to COVID-19 infection and vaccination.Demonstrated the capacity of Spike variants neutralization is associated with the diversity of anti-Spike antibodies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Natural Science Foundation of China (31870823), National Key R&D Program of China (2020YFE0202200), State Key Laboratory of Proteomics (SKLP-C202001, SKLP-O201904, SKLP-O201703, SKLP-O202007), the National Program on Key Basic Research Project (2018YFA0507503, 2017YFC0906703, 2018ZX09733003) and the Beijing Municipal Education Commission, Beijing Municipal Natural Science Foundation (M21003) and Beijing Municipal Science＆Technology Commission (Z201100001020001; Z201100005420022). We thank Dr. Brianne Petritis for her critical review and editing of this manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Our research was approved by the Ethics Committee of Beijing Ditan Hospital (No. 2021-010-01), and exemption of informed consent was obtained prior to sera collection.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe ability of the serological NAbs to inhibit the S-ACE2 interactions across the different S variants was visualized as a heatmap using the MultiExperiment Viewer software version 4.9 (Chu et al., 2008). Statistical analyses were performed using the GraphPad Prism software 8.3 and Microsoft Excel with the unpaired t test and Mann-Whitney test. A p-value (p) < 0.05 was considered to be significant. *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001. The 3D structure of the SARS-CoV-2 RBD and ACE2 complex (PDB ID code: 6M0J) was visualized using the VMD 1.9.3, and mutations were annotated.